脾切除术治疗免疫性血小板减少症:应用减少但并未退出
脾切除术是类固醇难治性或依赖性免疫性血小板减少症(ITP)的有效疗法,可去除血小板清除和自身抗体产生的主要部位,持久缓解率50%至70%,高于其他ITP疗法。随着利妥昔单抗和血小板生成素受体激动剂等药物出现,脾切除术使用减少,一般保留给多种药物治疗失败者。缺乏可靠预测脾切除反应的指标,须考虑感染和心血管并发症的长期风险。
要点
- 脾切除术持久缓解率为50%至70%,高于其他ITP疗法。
- 脾切除术使用减少,一般保留给多种药物治疗失败的患者。
- 无可靠预测脾切除反应的指标,须考虑感染和心血管并发症长期风险。
核心结论
- 脾切除术对许多患者仍是合理的治疗选择,包括希望摆脱用药和监测的活跃生活方式患者以及对药物治疗反应不佳的暴发性ITP患者。
- 治疗决策必须根据患者合并症、生活方式和偏好个体化制定。
- 未来研究应侧重于比较不同二线疗法的长期结局,并开发个体化医学方法以识别最可能对脾切除术或其他疗法有反应的患者亚组。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 脾切除术去除血小板清除和自身抗体产生的主要部位,与其他ITP疗法相比提供最高的持久缓解率(50%至70%)。
- 脾切除术没有可靠的疗效预测指标,且必须考虑感染和心血管并发症的长期风险。
- 不同二线药物疗法对ITP的长期疗效尚未直接比较,治疗决策缺乏支持性证据。
关键数值与推荐
- 脾切除术持久缓解率为50%至70%。
- 不同二线药物疗法对ITP的长期疗效尚未直接比较。
临床怎么用
- 脾切除术仍是许多患者的合理治疗选择,包括希望摆脱用药和监测的活跃生活方式患者以及对药物治疗反应不佳的暴发性ITP患者。
- 对大多数患者,本研究中心的做法是尽量避免在ITP诊断后12个月内行脾切除术,以允许自发或治疗诱导的缓解,尤其是手术并发症风险较高且缓解率较低的老年患者和年幼儿童。
- 治疗决策必须根据患者合并症、生活方式和偏好个体化制定。
局限性
- 没有可靠的脾切除术疗效预测指标。
- 不同二线药物疗法对ITP的长期疗效尚未直接比较,治疗决策缺乏支持性证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Splenectomy is an effective therapy for steroid-refractory or dependent immune thrombocytopenia (ITP). With the advent of medical alternatives such as rituximab and thrombopoietin receptor antagonists, the use of splenectomy has declined and is generally reserved for patients that fail multiple medical therapies. Splenectomy removes the primary site of platelet clearance and autoantibody production and offers the highest rate of durable response (50% to 70%) compared with other ITP therapies. However, there are no reliable predictors of splenectomy response, and long-term risks of infection and cardiovascular complications must be considered. Because the long-term efficacy of different second-line medical therapies for ITP have not been directly compared, treatment decisions must be made without supportive evidence. Splenectomy continues to be a reasonable treatment option for many patients, including those with an active lifestyle who desire freedom from medication and monitoring, and patients with fulminant ITP that does not respond well to medical therapy. We try to avoid splenectomy within the first 12 months after ITP diagnosis for most patients to allow for spontaneous or therapy-induced remissions, particularly in older patients who have increased surgical morbidity and lower rates of response, and in young children. Treatment decisions must be individualized based on patients' comorbidities, lifestyles, and preferences. Future research should focus on comparing long-term outcomes of patients treated with different second-line therapies and on developing personalized medicine approaches to identify subsets of patients most likely to respond to splenectomy or other therapeutic approaches.
引用
- Chaturvedi S, Arnold DM, McCrae KR, et al. Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018. PMID: 29295846. doi:10.1182/blood-2017-09-742353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。